Current Gastroenterology Reports最新文献_第8页

Fecal Microbiota Transplantation for Disorders of Gut-Brain Interaction: Current Insights, Effectiveness, and Future Perspectives. 粪便微生物群移植治疗肠-脑相互作用疾病：当前的见解，有效性和未来的前景。

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-07-09 DOI: 10.1007/s11894-025-01001-6

Taha Bin Arif, John A Damianos, Asad-Ur- Rahman, Nimra Hasnain

{"title":"Fecal Microbiota Transplantation for Disorders of Gut-Brain Interaction: Current Insights, Effectiveness, and Future Perspectives.","authors":"Taha Bin Arif, John A Damianos, Asad-Ur- Rahman, Nimra Hasnain","doi":"10.1007/s11894-025-01001-6","DOIUrl":"10.1007/s11894-025-01001-6","url":null,"abstract":"Purpose of review: Dysbiosis can disrupt intestinal barrier integrity and impact the immune and nervous systems, playing a significant role in developing disorders of gut-brain interaction (DGBI). This review aims to provide a comprehensive understanding of dysbiosis and its role in DGBI while examining the latest advancements in fecal microbiota transplantation (FMT). It also highlights key challenges in the field and outlines critical directions for future research to optimize FMT strategies, ultimately improving patient outcomes in this evolving treatment area.Recent findings: In DGBI, dysbiosis triggers immune responses, increases gut permeability, and disrupts nervous system signaling, with contributing factors including diet, antibiotics, stress, and infections. Individuals with DGBI exhibit distinct microbial imbalances, such as an increased Firmicutes-to-Bacteroidetes ratio and reduced beneficial bacteria. FMT has shown mixed results, with factors like patient selection, treatment protocols, and microbiome diversity influencing outcomes. While FMT can improve symptoms in refractory irritable bowel syndrome (IBS), effects may fade over time, requiring repeat treatments. Future FMT approaches should focus on targeted microbial interventions, considering the role of archaea, fungi, and microbial metabolites, while prioritizing optimal donor selection and large-scale trials for long-term efficacy. Despite the promising findings, FMT has not yet been widely endorsed in clinical guidelines due to the variability and heterogeneity of the data available. While much of the research has focused on IBS, studies have also explored the impact of FMT on other conditions such as functional diarrhea, functional constipation, and functional dyspepsia, which all exhibit altered microbial profiles.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"50"},"PeriodicalIF":4.1,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastrointestinal Motility Effects of GLP-1 Receptor Agonists. GLP-1受体激动剂对胃肠运动的影响。

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-07-07 DOI: 10.1007/s11894-025-00995-3

Danielle Bellavance, Samantha Chua, Hiroshi Mashimo

{"title":"Gastrointestinal Motility Effects of GLP-1 Receptor Agonists.","authors":"Danielle Bellavance, Samantha Chua, Hiroshi Mashimo","doi":"10.1007/s11894-025-00995-3","DOIUrl":"10.1007/s11894-025-00995-3","url":null,"abstract":"Purpose of review: This review summarizes the current understanding of the physiologic influence of GLP-1 RAs on gastrointestinal motility, highlights key clinical implications of these effects, and defines areas for future investigation.Recent findings: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the treatment of diabetes and obesity and are increasingly being identified as promising therapies for a wide range of conditions. GLP-1 RAs mimic naturally occurring GLP-1, an enterohormone produced in response to oral intake that regulates glucose metabolism and promotes weight loss. While GLP-1 RAs target a wide range of organ systems, their impacts on gastrointestinal motility are widely regarded as a major mechanism by which they exert their metabolic effects. However, the drugs' alterations in gut motility may account for many of their commonly reported adverse effects including nausea, vomiting, early satiety, dyspepsia, and bowel habit changes. GLP-1 RAs alter gastrointestinal motility at all levels of the GI tract, with delayed gastric emptying being the most well characterized. The effects of GLP-1 RAs on gastrointestinal motility have important clinical implications, including possible increased periprocedural aspiration risk and potential challenges with medication adherence and tolerability.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"49"},"PeriodicalIF":4.1,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Postpartum Anorectal and Pelvic Floor Disorders: Evaluation, Treatment, and Prevention. 产后肛门直肠和盆底疾病：评估、治疗和预防。

Current Gastroenterology Reports Pub Date : 2025-07-03 DOI: 10.1007/s11894-025-01000-7

Lalitha Sitaraman, Christina Lewicky-Gaupp, Satish Sc Rao

{"title":"Postpartum Anorectal and Pelvic Floor Disorders: Evaluation, Treatment, and Prevention.","authors":"Lalitha Sitaraman, Christina Lewicky-Gaupp, Satish Sc Rao","doi":"10.1007/s11894-025-01000-7","DOIUrl":"10.1007/s11894-025-01000-7","url":null,"abstract":"Purpose of review: Postpartum anorectal and pelvic floor disorders (PFD) are common, though under-recognized. There is limited knowledge regarding their diagnosis, treatment, and prevention. Here we provide a critical review of this topic and highlight knowledge gaps and treatment options for these problems.Recent findings: Recent advances include dynamic 3D and 4D ultrasound of the pelvic floor to reveal pathology, anal sphincter defects, and pelvic organ prolapse. Treatments for fecal incontinence include anal inserts, vaginal inserts, translumbosacral neuromodulation therapy (not yet studied postpartum), and increasing data for safety of sacral nerve stimulators in pregnancy. Exercise, pelvic floor muscle training, and use of special devices show mixed results. Postpartum anorectal and pelvic floor disorders include fecal and/or flatus incontinence, constipation, hemorrhoids, pelvic organ prolapse, and urinary incontinence. Many patients present years later, and most suffer in silence. Early recognition, appropriate treatment, and preventative measures could mitigate these problems.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"48"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Underwater Endoscopy: Diving into the Future of Gastrointestinal Endoscopy. 水下内窥镜：潜入胃肠道内窥镜的未来。

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-06-30 DOI: 10.1007/s11894-025-00993-5

Garvit Chhabra, Amal Shine, Nanlong Liu

引用次数: 0

A Guide Through the Tunnel: Updates in the Approach to Classification and Management of Perianal Fistulizing Crohn's Disease. 隧道指南：肛门周围瘘管性克罗恩病分类和治疗方法的最新进展。

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-06-27 DOI: 10.1007/s11894-025-00998-0

WonKyung J Cho, Serre-Yu Wong

{"title":"A Guide Through the Tunnel: Updates in the Approach to Classification and Management of Perianal Fistulizing Crohn's Disease.","authors":"WonKyung J Cho, Serre-Yu Wong","doi":"10.1007/s11894-025-00998-0","DOIUrl":"10.1007/s11894-025-00998-0","url":null,"abstract":"Purpose of review: Perianal fistulizing Crohn's disease (PFCD) is a severe and debilitating phenotype of Crohn's disease that presents significant clinical and therapeutic challenges. This review aims to outline a practical approach to classification and management, emphasizing the utility of the TOpClass system.Recent findings: The TOpClass classification incorporates clinical and anatomic characteristics to assess severity, treatment options, and patient-clinician goals. Post-hoc analyses from clinical trials for the Janus kinase inhibitor Upadacitinib and emerging data on IL-23 receptor antagonists suggest potential roles beyond anti-TNFs, while the broader use of mesenchymal stem cell therapy remains limited due to inconsistent efficacy. Fistula conditioning with curettage and internal opening closure-an underutilized technique-alongside adjunctive therapies such as hyperbaric oxygen therapy (HBOT), has shown promise in promoting wound healing in select patients. The TOpClass classification, by integrating patient-centered factors and multidisciplinary management, offers a comprehensive and adaptable framework for PFCD, addressing key gaps in treatment planning, standardization, and research. The classification will enable tailored, evidence-based care across the disease spectrum.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"46"},"PeriodicalIF":4.1,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Diagnostics for the Evaluation of Neurogastroenterology & Motility Disorders: Are They Ready for Prime Time? 神经胃肠病学和运动障碍的诊断评估进展：它们准备好了吗？

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-06-27 DOI: 10.1007/s11894-025-00999-z

Lavanya Viswanathan, Baharak Moshiree

引用次数: 0

Correction To: The Neuroimmune Axis in Gastrointestinal Disorders- An Underrecognized Problem. 纠正：胃肠疾病中的神经免疫轴-一个未被认识的问题。

Current Gastroenterology Reports Pub Date : 2025-06-26 DOI: 10.1007/s11894-025-00983-7

Laura A Pace, Niwen Kong, Mohamed I Itani, James Hemp

引用次数: 0

The Impact of Specialized Pro-Resolving Mediators on Disease Activity and the Risk of Associated Colorectal Carcinoma in Inflammatory Bowel Disease. 炎性肠病中特异性促解介质对疾病活动和相关结直肠癌风险的影响

IF 4.1

Current Gastroenterology Reports Pub Date : 2025-06-24 DOI: 10.1007/s11894-025-00997-1

Jennifer Katz, Stephanie Gold, Vikram J Christian, Robert Martindale

{"title":"The Impact of Specialized Pro-Resolving Mediators on Disease Activity and the Risk of Associated Colorectal Carcinoma in Inflammatory Bowel Disease.","authors":"Jennifer Katz, Stephanie Gold, Vikram J Christian, Robert Martindale","doi":"10.1007/s11894-025-00997-1","DOIUrl":"10.1007/s11894-025-00997-1","url":null,"abstract":"Purpose of review: The purpose of this review is to explore the role of specialized pro-resolving mediators (SPMs) in the resolution of inflammation in inflammatory bowel disease (IBD) focusing on their potential therapeutic benefits in these conditions.Recent findings: IBD is characterized by chronic inflammation and mucosal barrier dysfunction, driven by a dysregulated immune response. SPMs, which are derived from polyunsaturated fatty acids, have been identified as active agents in resolving inflammation without impairing immune function. Preclinical studies indicate that SPMs can reduce intestinal inflammation, but clinical data are still limited. Moreover, SPMs may influence colorectal cancer (CRC) by modulating tumor-promoting inflammation and enhancing chemotherapy response. SPMs offer a promising approach to inflammation resolution and mucosal healing in IBD and CRC. However, further research is necessary to better understand their therapeutic potential and to establish their clinical applicability in these diseases.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"43"},"PeriodicalIF":4.1,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of Colonic Diverticular Disease in the Older Adult. 老年人结肠憩室疾病的治疗。

Current Gastroenterology Reports Pub Date : 2025-06-21 DOI: 10.1007/s11894-025-00986-4

Hiep S Phan, Lisa L Strate

{"title":"Management of Colonic Diverticular Disease in the Older Adult.","authors":"Hiep S Phan, Lisa L Strate","doi":"10.1007/s11894-025-00986-4","DOIUrl":"10.1007/s11894-025-00986-4","url":null,"abstract":"Purpose of review: While societal guidelines help direct management of diverticulitis and diverticular bleeding broadly, our review focuses on the latest data for nuanced care of older patients affected by these conditions.Recent findings: Diverticulitis in older patients can present with non-specific symptoms so a broad work up is recommended. Once diagnosed, those with uncomplicated disease (Hinchey Class 0 or 1a) can be safely managed without antibiotics or admission depending on frailty and comorbidities. Most older patients with complicated diverticulitis (abscess, perforation or obstruction) should be hospitalized. Elective or emergent surgery for complicated disease (Hinchey Class 1b-4) is associated with higher morbidity and mortality, particularly in older patients. The risk of diverticular bleeding and re-bleeding significantly increases with age, potentially due to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and anticoagulants. Diverticular disease and its associated complications disproportionately affect older adults. Management should focus on resuscitation, having low threshold for comprehensive work up and re-evaluating medication use for comorbid conditions to prevent recurrence.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"42"},"PeriodicalIF":0.0,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applying Biomarkers in Treat-to-target Approach for IBD. 生物标志物在IBD从治疗到靶向治疗中的应用

Current Gastroenterology Reports Pub Date : 2025-06-20 DOI: 10.1007/s11894-025-00991-7

Megan Lutz, Sara Horst, Freddy Caldera

{"title":"Applying Biomarkers in Treat-to-target Approach for IBD.","authors":"Megan Lutz, Sara Horst, Freddy Caldera","doi":"10.1007/s11894-025-00991-7","DOIUrl":"10.1007/s11894-025-00991-7","url":null,"abstract":"Purpose of review: The treatment of inflammatory bowel disease (IBD) has evolved significantly over time based on \"treat-to-target\", an approach which uses sequential objective makers to monitor response to therapy with the ultimate goal of achieving endoscopic healing. Biomarkers, including C-reactive protein and fecal calprotectin, are an important noninvasive intermediate step in this treatment approach as well as in routine monitoring of disease activity. While widely utilized, there is significant variability and some uncertainty in biomarker implementation; this review summarizes evidence for the use of biomarkers in IBD.Recent findings: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) update in combination with the 2023 American Gastroenterological Association (AGA) guidelines on the role of biomarkers in the management of both Crohn's disease and ulcerative colitis have offered significant new guidance for those who manage IBD. Biomarkers offer important insight into disease activity and can be used to track progress toward deeper levels of remission in IBD.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"41"},"PeriodicalIF":0.0,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0